Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
-
New CAR t therapy targets hidden lymphoma cells after initial treatment
Disease control Recruiting nowThis study tests a new cell therapy called cemacabtagene ansegedleucel (cema-cel) in adults with large B-cell lymphoma who still have tiny amounts of cancer cells (minimal residual disease) after finishing their first standard treatment. About 250 participants will be randomly as…
Phase: PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Engineered immune cells take on autoimmune diseases in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC